A rational approach to the treatment of hepatic encephalopathy in patients with liver cirrhosis
https://doi.org/10.22625/2072-6732-2012-4-4-32-41
Abstract
In 125 patients with liver cirrhosis of different etiologies, classes A, B and C according to the Child-Pugh, with minimal hepatic encephalopathy and overt encephalopathy to II grade according to the West Haven criteria, we studied the efficacy of treatment of hepatic encephalopathy drugs of different pharmacological groups. The highest efficiency was found in the treatment with Stimol, treatment with probiotics and treatment included the combination of probiotics with metronidazole. Treatment with these drugs showed improvement in clinical status and in psychometric (cognitive) performance, as well as positive changes in clinical and biochemical parameters of blood. Also, this treatment was associated with the improving the quality of life of patients.
About the Authors
K. V. Zhdanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
D. A. Gusev
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
S. M. Zakharenko
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
M. V. Kurtukov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
K. V. Kozlov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
V. S. Sukachev
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
A. S. Sigidaev
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
M. S. Talantseva
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
References
1. Подымова, С.Д. Болезни печени : руководство /С.Д. Подымова. – 4-е изд., перераб. и доп. – М.: Медицина, 2005. – 768 с.
2. Ferenci, P. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998 / P. Ferenci [et al.] // J. Hepatol. – 2002. – V. 35. – P. 716–721.
3. Bircher, J. Oxford Textbook of Clinical Hepatology /J. Bircher [et al.]. – 2nd edition. – New York.: Oxford University Press, 1999. – Р. 764–783.
4. Poordad, F.F. Review article: the burden of hepatic encephalopathy / F.F. Poordad // Aliment. Pharmacol. Ther. – 2007. – V. 25. (Suppl. 1). – P. 3–9.
5. Schalm, S.W. Subclinical hepatic encephalopathy impairs daily functioning / S.W. Schalm // J. Hepatol. – 1998. – V. 28. – P. 45–49.
6. Bajaj, J.S. Review article: the modern management of hepatic encephalopathy / J.S. Bajaj // Aliment. Pharmacol. Ther. – 2010. – V. 31. – P. 537–547.
7. Chung, R.T. Cirrhosis and its complications / R.T. Chung, D. Podolsky // In Harrison’s Principles of Internal Medicine /D.L. Kasper, E. Braunwald, A.S. Fauci, eds. – 16th edition. – New York.: McGraw-Hill, 2005. – P. 1858–1869.
8. Shawcross, D.L. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis / D.L. Shawcross [et al.] // J. Hepatol. – 2004. – V. 40. – P. 247–254.
9. Zhao, H.Y. Intestinal microflora in patients with liver cirrhosis / H.Y. Zhao [et al.] // Chin. J. Dig. – 2004. – V. 5. – P. 64–67.
10. Liu, Q. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis / Q. Liu [et al.] // J. Heptol. – 2004. – V. 39. – P. 1441–1449.
11. Marchesini G. Zinc supplementation and amino acidnitrogen metabolism in patients with advanced cirrhosis / G. Marchesini [et al.] // J. Hepatol. – 1996. – V. 23. – P. 1084–1092.
12. Sidhu, S.S. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial) / S.S. Sidhu [et al.] // Am. J. Gastroenterol. – 2011. – V. 106. – P. 307–316.
13. Morgan, M.H. Treatment of hepatic encephalopathy with metronidazole / M.H. Morgan, A.E. Read, D.C. Speller //Gut. – 1982. – V. 23. – P. 1–7.
14. Dhiman, R.K. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy / R.K. Dhiman [et al.] // Dig. Dis. Sci. – 2000. – V. 45. – P. 1549–1552.
15. Mittal, V.V. Treatment of minimal hepatic encephalopathy: A randomised controlled trial comparing lactulose, probiotics and l-ornithine l-aspartate with placebo / V.V. Mittal [et al.] // J. Hepatol. – 2009. – 50 (Suppl). – 471A.
16. Plauth, M. Longterm treatment of latent portosystemic encephalopathy with branched-chain amino acids: a double blind placebo-controlled cross over study / M. Plauth [et al.] // J. Hepatol. – 1993. – V. 17. – P. 308–314.
17. Liu, Q. Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis / Q. Liu [et al.] // J. Hepatol. – 2004. – V. 39. – P. 1441–1449.
18. Folstein, M.F. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician /M.F. Folstein, S.E. Folstein, P.R. McHugh // J. Psychiatr. Res. – 1975. – V. 12. – P. 189–198.
19. Новик, А.А. Руководство по исследованию качества жизни в медицине / А.А. Новик, Т.И. Ионова ; под ред. Ю.Л. Шевченко. – 2-e изд., перераб. и доп. – М.: ОЛМА- ПРЕСС, 2007. – 313 с.
20. Практическое руководство Всемирного гастроэнтерологического общества (ВГО). Лечение асцита, осложняющего цирроз печени у взрослых // Рос. журн. гастроэнтерол., гепатол., колопроктол. – 2007. – Т. 17, № 4. – С. 82–88.
21. Loft, S. Metronidazole pharmacokinetics in patients with hepatic encephalopathy / S. Loft [et al.] // Scand. J. Gastroenterol. – 1987. – V. 22. – P. 117–123.
22. Muscará, M.N. Plasma hydroxy-metronidazole /metronidazole ratio in patients with liver disease and in healthy volunteers / M.N. Muscará [et al.] // Br. J. Clin. Pharmacol. – 1995. – V. 40. – P. 477–480.
23. Malaguarnera, M. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double blind, placebocontrolled study / M. Malaguarnera [et al.] // Dig. Dis. Sci. – 2007. – V. 52. – P. 3259–3265.
24. Briand, J. Use of a microbial model for the determination of drug effects on cell metabolism and energetics: study of citrulline malate / J. Briand [et al.] // Biopharmaceutics & Drug Disposition. – 1992. – V. 13. – P. 1–22.
25. Goubel, F. Citrulline malate limits increase in muscle fatigue induced by bacterial endotoxin / F. Goubel [et al.] //Can. J. Physiol. Pharmacol. – 1997. – V. 75. – P. 205–207.
26. Callis, A. Activity of citrulline malate on acid-base balance and blood ammonia and amino acid levels. Study in the animal and in man / A. Callis [et al.] // Drug. Res. – 1991. – V. 41. – P. 660–663.
Review
For citations:
Zhdanov K.V., Gusev D.A., Zakharenko S.M., Kurtukov M.V., Kozlov K.V., Sukachev V.S., Sigidaev A.S., Talantseva M.S. A rational approach to the treatment of hepatic encephalopathy in patients with liver cirrhosis. Journal Infectology. 2012;4(4):32-41. (In Russ.) https://doi.org/10.22625/2072-6732-2012-4-4-32-41
Views:
684
.png)
.png)
Email this article 